ProMIS Neurosciences Inc PMN

Unanimous 11-0

[Trek1701]

https://www.forbes.com/sites/joshuacohen/2024/06/11/alzheimers-disease-drug-donanemab-gets-unanimous-backing-from-fda-expert-panel/

1736 patients enrolled in p3.
25% ARIA.
5% underrepresented???
39% lower risk of progressing to the next stage.
Role of Tau biomarker.
Proposed dosing regimen may be stopped once the plaque is cleared.

[G1945V]

"The main safety concerns of donanemab are brain swelling (edema) and micro-bleeding (hemorrhages), both known as amyloid-related imaging abnormalities, or ARIA. In the clinical trial, among people receiving donanemab, micro-bleeding occurred in 31.4% and brain swelling in 24%." G1945V

[Gbathat]

Yikes, 31% ARIA-E for donanemab  How PMN is still not financed through Ph2 or bought out at this point is beyond me.